user

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

被引：0
|
作者：
Adrián Sanz-Moreno
Sonia Palomeras
Kim Pedersen
Beatriz Morancho
Tomas Pascual
Patricia Galván
Sandra Benítez
Jorge Gomez-Miragaya
Marina Ciscar
Maria Jimenez
Sonia Pernas
Anna Petit
María Teresa Soler-Monsó
Gemma Viñas
Mansour Alsaleem
Emad A. Rakha
Andrew R. Green
Patricia G. Santamaria
Celine Mulder
Simone Lemeer
Joaquin Arribas
Aleix Prat
Teresa Puig
Eva Gonzalez-Suarez
机构：
[1] Oncobell,Present Address: German Mouse Clinic
[2] Bellvitge Biomedical Research Institute (IDIBELL),New Therapeutics Targets Lab (TargetsLab), Department of Medical Sciences
[3] L’Hospitalet de Llobregat,Preclinical Research Program
[4] Institute of Experimental Genetics,Department of Medical Oncology
[5] HMGU,Present Address: Department of Biomedicine, Department of Surgery
[6] University of Girona,Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology (ICO)
[7] Vall d’Hebron Institute of Oncology (VHIO),Pathology Department
[8] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),Medical Oncology Department
[9] Translational Genomics and Targeted Therapeutics in Solid Tumors,Division of Cancer and Stem Cells, School of Medicine
[10] August Pi i Sunyer Biomedical Research Institute (IDIBAPS),Biomolecular Mass Spectrometry and Proteomics Bijvoet Center
[11] SOLTI Breast Cancer Research Group,Medicine Department
[12] Hospital Clinic,undefined
[13] University Hospital Basel,undefined
[14] University of Basel,undefined
[15] Molecular Oncology,undefined
[16] Spanish National Cancer Research Centre (CNIO),undefined
[17] University Hospital of Bellvitge IDIBELL,undefined
[18] L’Hospitalet de Llobregat,undefined
[19] University Hospital of Bellvitge,undefined
[20] IDIBELL,undefined
[21] Catalan Institute of Oncology (ICO),undefined
[22] University of Nottingham Biodiscovery Institute,undefined
[23] Utrecht University,undefined
[24] University of Barcelona,undefined
来源：
Breast Cancer Research | / 23卷
关键词：
Breast cancer; HER2; Lapatinib; NF-κB; RANK; RANKL; Resistance; Trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
    Sanz-Moreno, Adrian
    Palomeras, Sonia
    Pedersen, Kim
    Morancho, Beatriz
    Pascual, Tomas
    Galvan, Patricia
    Benitez, Sandra
    Gomez-Miragaya, Jorge
    Ciscar, Marina
    Jimenez, Maria
    Pernas, Sonia
    Petit, Anna
    Soler-Monso, Maria Teresa
    Vinas, Gemma
    Alsaleem, Mansour
    Rakha, Emad A.
    Green, Andrew R.
    Santamaria, Patricia G.
    Mulder, Celine
    Lemeer, Simone
    Arribas, Joaquin
    Prat, Aleix
    Puig, Teresa
    Gonzalez-Suarez, Eva
    [J]. BREAST CANCER RESEARCH, 2021, 23 (01)
  • [2] Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy
    Sethunath, Vidyalakshmi
    Hu, Huizhong
    De Angelis, Carmine
    Veeraraghavan, Jamunarani
    Qin, Lanfang
    Rimawi, Motthaffar F.
    Osborne, Kent C.
    Schiff, Rachel
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [3] De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer
    Madrid-Paredes, Adela
    Canadas-Garre, Marisa
    Sanchez-Pozo, Antonio
    Angel Calleja-Hernandez, Miguel
    [J]. PHARMACOGENOMICS, 2015, 16 (12) : 1411 - 1426
  • [4] Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes
    Watanabe, Kenichi
    Hagio, Kanako
    Baba, Motoi
    Ikarashi, Mayuko
    Sato, Masako
    Tomioka, Nobumoto
    Takahashi, Masato
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [5] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    [J]. CANCER CONTROL, 2023, 30
  • [6] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    [J]. CANCER CONTROL, 2022, 29
  • [7] HER2-positive breast cancer: From trastuzumab to innovatory anti-HER2 strategies
    Whenham, Nicolas
    D'Hondt, Veronique
    Piccart, Martine J.
    [J]. CLINICAL BREAST CANCER, 2008, 8 (01) : 38 - 49
  • [8] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [9] Loss of androgen receptor after neoadjuvant anti-HER2 therapy in patients with locally advanced HER2-positive breast cancer
    Espinosa Fernandez, Jose Rodrigo
    Sahin, Aysegul A.
    Hess, Kenneth R.
    Ramirez Medina, Raul Gerardo
    Cabrera Galeana, Paula Anel
    Espana Ferrufino, Alejandro Javier
    Esparza Arias, Nereida
    Bargallo Rocha, Juan Enrique
    Garcia Gordillo, Jose Antonio
    Lopez Muniz, Gerardo Emmanuel
    Ueno, Naoto T.
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [10] Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
    Madrid-Paredes, Adela
    Canadas-Garre, Marisa
    Sanchez-Pozo, Antonio
    Angel Calleja-Hernandez, Miguel
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 493 - 505
12345